The Written Informed Consent Act directs the Secretary of Veterans Affairs to update VHA Directive 1005 (Informed Consent For Long-term Opioid Therapy For Pain, May 13, 2020) so that the directive’s requirements apply not only to long-term opioid therapy but also to antipsychotics, stimulants, antidepressants, anxiolytics, and narcotics. It is an administrative instruction: the bill orders an internal change to a VA directive rather than creating new criminal penalties or an independent statutory consent regime.
The change matters because it broadens written informed-consent obligations inside the VA health system to classes of medications commonly used for mental health and chronic conditions. That expansion will affect prescribing workflows, clinical documentation, patient counseling, and compliance systems across VA medical centers and clinics, with attendant operational and access trade-offs for clinicians and patients alike.
At a Glance
What It Does
The bill requires the Secretary of Veterans Affairs to revise VHA Directive 1005 so that the directive’s informed-consent processes apply to five additional medication classes: antipsychotics, stimulants, antidepressants, anxiolytics, and narcotics. The directive named in the bill is the VA’s May 13, 2020 document on informed consent for long‑term opioid therapy.
Who It Affects
The requirement applies to VA providers, pharmacists, compliance officers, and medical records staff who operate within the Veterans Health Administration and prescribe or manage the listed medication classes. Veterans receiving these medications in VA facilities and integrated community care paid or coordinated by VA will be directly affected by any new consent and documentation practices.
Why It Matters
Expanding an internal VA informed‑consent directive to cover common mental‑health and controlled substances could standardize patient counseling and risk disclosure across VA care, but also increase administrative burden and potentially alter clinical access pathways where expedited treatment is common. For compliance and quality teams, it creates a focused administrative change to plan for rather than a broad new statutory regime.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill instructs the Secretary of Veterans Affairs to change an existing VHA directive—VHA Directive 1005, a May 13, 2020 policy that governs written informed consent for long‑term opioid therapy—so that the directive governs five additional classes of medications. Because the bill points to an internal directive rather than drafting a stand‑alone statutory framework, the resulting obligations will flow through VA administrative policy and implementation guidance rather than creating new statutory rights or penalties.
Operationally, updating Directive 1005 will likely mean that prescribing clinicians in VA settings must follow the directive’s informed‑consent steps when initiating or continuing long‑term treatment with antipsychotics, stimulants, antidepressants, anxiolytics, and narcotics. That could include standardized disclosure of risks and benefits, documentation of consent in the medical record, and any monitoring or follow‑up procedures specified by the directive.
The bill itself does not define 'long‑term' for the added classes, nor does it set a schedule for the Secretary to complete the update.Because several of the specified classes (for example, stimulants and many antipsychotics) include controlled substances or carry specific safety monitoring needs, extending the opioid‑therapy consent template across diverse drug classes will force program managers to reconcile a single directive’s structure with distinct clinical workflows. The change is limited to VHA operations; it does not directly change private‑sector or non‑VA federal providers’ consent obligations, although VA community care arrangements may have to adopt consistent documentation if VA requires it.Finally, the bill is short and narrowly focused: it mandates an administrative revision rather than prescribing the text of new consent requirements.
That means much of the detail—how consent forms look, what risks must be disclosed, how to handle emergency prescribing, who must sign, and how to train staff—will be left to VA to specify when updating the directive and any accompanying implementation guidance.
The Five Things You Need to Know
The bill names VHA Directive 1005 (dated May 13, 2020) and requires the Secretary of Veterans Affairs to revise that directive so its informed‑consent protocols apply to five additional medication classes.
The five classes added are explicitly: antipsychotics, stimulants, antidepressants, anxiolytics, and narcotics—language that creates overlap and ambiguity with the directive’s existing focus on opioids.
The statute is an administrative command to update an internal VA directive; it does not create new criminal penalties, federal reporting mandates, or an independent statutory consent form.
The bill contains no implementation timeline, funding authorization, or enforcement mechanism—leaving scheduling, training, and compliance to VA leadership and existing administrative processes.
Because 'narcotics' and 'stimulants' include federally controlled substances (including many Schedule II drugs), the directive update could intersect with controlled‑substance monitoring and pharmacy safeguards already in VA systems.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Gives the act the official name 'Written Informed Consent Act.' This section has no operational effect beyond the statutory short title but signals the bill’s narrow focus on consent policy inside the VA.
Directive update mandate
Commands the Secretary of Veterans Affairs to update VHA Directive 1005 so that its informed‑consent requirements apply to additional medication classes. Practically, this obligates VA leadership to amend internal policy documents and any linked procedures—consent forms, training modules, and electronic health record templates—to reflect the new scope.
Specified medication classes
Lists the five medication classes to be added: antipsychotics, stimulants, antidepressants, anxiolytics, and narcotics. The instruction is class‑based rather than indication‑based (it does not say, for example, 'for chronic mental illness' or 'for long‑term use' beyond the directive’s original opioid focus), which will require VA to interpret how the directive’s provisions map to each class in practice.
Administrative, not statutory, change; no timeline
Because the bill directs an update to an internal VHA directive rather than prescribing its text, the substance and timing of the new informed‑consent procedures will be determined through VA rulemaking or internal administrative processes. The bill does not appropriate funds or require the Secretary to issue implementing guidance by a specific date, so implementation pace and resourcing remain discretionary.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Veterans receiving mental‑health or chronic‑condition medications — they will receive formalized written disclosures and likely more consistent counseling about risks, benefits, and alternatives when treated within VA facilities.
- Patient‑advocacy and oversight offices inside VA — standardized consent protocols will create clearer documentation trails for audit, grievance review, and quality improvement.
- VHA compliance and quality teams — a single directive covering multiple classes can simplify policy oversight by creating unified standards for informed consent within the VA system.
Who Bears the Cost
- VA prescribers and clinic staff — they will face added documentation, counseling, and possibly monitoring steps, increasing visit length and administrative workload.
- VHA administration — facilities will incur training, IT changes (consent forms in EHR), and policy drafting costs without an appropriation in the bill.
- Veterans seeking rapid initiation of care — added consent steps could delay prescribing or create procedural barriers in situations where clinicians judge quick access necessary (e.g., acute stabilization).
Key Issues
The Core Tension
The central dilemma is between enhancing patient autonomy through standardized written informed consent and preserving timely, flexible clinical access: tighter consent and documentation improve transparency and oversight but also increase clinician workload and can slow access to medications that clinicians consider urgently needed.
The bill’s brevity creates practical ambiguities. It points to an internal directive and a date (May 13, 2020) but leaves to the Secretary the critical decisions about what 'applying' that directive means for each drug class.
VHA Directive 1005 was written for long‑term opioid therapy and may include opioid‑specific monitoring (e.g., urine drug testing, opioid risk assessments) that do not translate neatly to antidepressants or antipsychotics. VA must decide whether to adopt the opioid template wholesale, to adapt elements class‑by‑class, or to craft entirely new consent sub‑forms — choices with real clinical consequences.
Another area of tension is terminology and overlap: the bill uses both 'narcotics' and, by reference, the opioid‑focused directive; those terms are not synonymous in contemporary clinical parlance. That ambiguity can cause inconsistent application across facilities and complicate integration with controlled‑substance monitoring programs.
Finally, because the statute imposes an administrative mandate without funding or deadlines, implementation quality and timing will depend on competing VA priorities and local capacity, risking a patchwork rollout that undermines the uniformity the bill seems to intend.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.